Amin Sanjiv B, Sinkin Robert A, Glantz J Christopher
Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.
Am J Obstet Gynecol. 2007 Nov;197(5):486.e1-10. doi: 10.1016/j.ajog.2007.04.019.
The objective of the study was to determine whether indomethacin used as a tocolytic agent is associated with adverse neonatal outcomes.
We used published guidelines of the Metaanalysis of Observational Studies in Epidemiology Group (MOOSE) to perform the metaanalysis. The search strategy used included computerized bibliographic searches of MEDLINE (1966-2005), PubMed (1966-2005), abstracts published in Obstetrics and Gynecology (1991-2005), abstracts published in Pediatric Research (1991-2005), and references of published manuscripts. Study inclusion criteria were publication in English, more than 30 deliveries less than 37 weeks' gestation, and meeting diagnostic criteria for individual neonatal outcomes. Exclusion criteria included case reports, case series, and multiple publications from the same author. Metaanalysis was performed using random effects model if there were more than 2 observational studies for a specific outcome. Eggers test was performed to exclude publication bias. Sensitivity analysis was performed to evaluate the effect of antenatal steroid exposure, gestation, and recent antenatal indomethacin exposure (duration of 48 hours or more between the last dose and delivery).
Fifteen retrospective cohort studies and 6 case-controlled studies met inclusion criteria. Antenatal indomethacin was associated with an increased risk of periventricular leukomalacia (odds ratio [OR], 2.0; 95% confidence interval [CI], 1.3-3.1). Recent exposure to antenatal indomethacin was associated with necrotizing enterocolitis (OR, 2.2; 95% CI; 1.1-4.2). Antenatal indomethacin was not associated with intraventricular hemorrhage, patent ductus arteriosus, respiratory distress syndrome, bronchopulmonary dysplasia, and mortality.
Antenatal indomethacin may be associated with an increased risk of periventricular leukomalacia and necrotizing enterocolitis in premature infants and therefore should be used judiciously for tocolysis.
本研究的目的是确定用作宫缩抑制剂的吲哚美辛是否与不良新生儿结局相关。
我们使用了流行病学观察性研究荟萃分析组(MOOSE)发布的指南来进行荟萃分析。所采用的检索策略包括对MEDLINE(1966 - 2005年)、PubMed(1966 - 2005年)进行计算机化文献检索,检索《妇产科学》(1991 - 2005年)发表的摘要、《儿科研究》(1991 - 2005年)发表的摘要以及已发表手稿的参考文献。研究纳入标准为以英文发表、妊娠少于37周的分娩数超过30例,且符合个体新生儿结局的诊断标准。排除标准包括病例报告、病例系列以及同一作者的多篇出版物。如果针对特定结局有超过2项观察性研究,则使用随机效应模型进行荟萃分析。进行Egger检验以排除发表偏倚。进行敏感性分析以评估产前类固醇暴露、孕周以及近期产前吲哚美辛暴露(最后一剂与分娩之间间隔48小时或更长时间)的影响。
15项回顾性队列研究和6项病例对照研究符合纳入标准。产前使用吲哚美辛与脑室周围白质软化风险增加相关(比值比[OR],2.0;95%置信区间[CI],1.3 - 3.1)。近期产前暴露于吲哚美辛与坏死性小肠结肠炎相关(OR,2.2;95% CI;1.1 - 4.2)。产前吲哚美辛与脑室内出血、动脉导管未闭、呼吸窘迫综合征、支气管肺发育不良及死亡率无关。
产前使用吲哚美辛可能会增加早产儿脑室周围白质软化和坏死性小肠结肠炎的风险,因此在用于抑制宫缩时应谨慎使用。